Biosimilars are one way that payers had hoped to bring down spending on pharmaceuticals, but as of yet, these products have had little impact in the United States. As of mid-January, the FDA had approved 17 biosimilars, but only a handful actually are available in the U.S. However, the products may pick up more traction in 2019, with some significant ones potentially coming to market.
- Abstract, Medicare and Medicaid
- Datapoint, Medicare and Medicaid
- Abstract, Specialty Pharmacy
- Datapoint, Drug Benefits
- Drug Benefits